Advertisement

Medical device company InfraReDx Inc. of Burlington said it has started a Phase 2 trial aimed at reducing heart attacks in stenting procedures, during which some 10 percent of patients experience cardiac problems.

While the trial aims to enroll only 108 patients, Sean Madden, principal scientist at InfraReDx, said that if successful, it could lead to a pivotal trial in which the company may seek additional indications from the U.S. Food and Drug Administration for its LipiScan IVUS (intravascular ultrasound), near-infrared coronary imaging system. The system won FDA approval in June 2010 and European CE Mark approval in April 2011.

SOURCE

Advertisement
Advertisement